The healthcare industry continues to grapple with uncertainty. The current macroeconomic environment, fast-changing Payer mix, and sustained investor expectations are pushing leaders into the tough ask of constantly recalibrating their strategies and learning to operate in the grey. ‘ Thinking, fast and slow’ was perhaps never more relevant than it is today. Healthcare leaders, while having to react to new market realities, must continue to tap into the huge opportunity potential that technologies such as AI, ChatGPT and Telehealth have to offer. Encouragingly, we are seeing a balancing act from both the industry executives and the regulators to thread the needle carefully in fostering faster patient innovations while recognizing the risks. Framing each challenge and solution with the Patient at the center, will go a long way in keeping the focus and making sustained progress toward a better healthcare ecosystem for the future.
|
Hybrid care delivery – Accelerating innovation agenda
|
| |
DXC perspective
COVID-19 accelerated the adoption of telehealth and care delivery beyond the traditional brick and mortar set up. As we emerge post pandemic, focus on enhancing the ease of access to care, seamless transition through care-continuum and overall improvement in experience continues to be a key driver in innovation. Many leading health systems are teaming up with digital platforms to bring the best foot forward when it comes to “customer delight.”
Dr. Urvashi Pathak
Industry Strategist, Provider
DXC Technology
|
|
|
Education on artificial intelligence amongst provider and patient
|
| |
|
DXC perspective
Clinicians are becoming more educated on the use of AI and how the models are trained. As their confidence builds, they are sharing with their patients and explaining the relevance of the technology. Ongoing education on AI for both clinicians and patients is vital to ensure open communication on its value. AI is an evolving technology that will continue to improve and change how healthcare is delivered.
Kelly Vroom
Industry Strategist, Provider
DXC Technology
|
|
|
|
Regulators showing real intent to stay abreast of AI movements in the market
|
| |
DXC perspective
Beginning of Mar-2023, FDA’s Center for Drug Evaluation and Research (CDER) published a discussion paper on artificial intelligence (AI) in drug manufacturing, seeking to gain industry and public perspectives to help shape future polity in this area. This is a particularly interesting development, coming on the heels of similar efforts in the medical devices space looking at AI-enabled devices.
Industry and regulators such as FDA, working in parallel to drive the fast-changing AI landscape, will allow the technology to be tapped swiftly for the illusive goals of accelerating innovation in Life Sciences to enable quicker availability of therapeutics to patients.
Ankur Chadha
Industry Strategist, Life Sciences
DXC Technology
|
|
|
Internet connected medical devices
|
| |
DXC perspective
The internet of things to remote monitor and manage common health issues has been growing steadily and has created access to better medical care for millions of patients.
But the ability to monitor medical conditions over the internet comes with risk including nefarious hacking. Medical device manufacturer and providers need to continue to have a strong focus on cybersecurity hygiene and put plans and processes in place to address vulnerabilities.
Gerson Benker
Industry Strategist, Medical Devices
DXC Technology
|
|
|
Clinical analytics insight for health plans
|
| |
DXC perspective
For most of us, the US Government Accountability Office (GAO) isn’t the number one agency we think of when talking about healthcare. If you haven’t visited the GAO Healthcare website, it’s worth the clicks (U.S. GAO - Health Care).
The report points out that the prevalence of obesity, as measured by BMI, is roughly 38% regardless of insurance/coverage status. That’s an interesting point as there is little difference in obesity prevalence in the insured and uninsured population.
Additionally, the report notes the high degree in variation in access and use to obesity treatments such as obesity medications. Of interest here is that the data pre-dates the introduction of the newest generation of weight management medications. These new medications may introduce even more variation into treatment access.
Health plans have an opportunity to proactively apply clinical analytics approaches to product and services designs as data becomes available on the impact of these new medications. Additionally, deeper dives into historical claims data and clinical notes, may allow for better approaches to coordination of behavioral health, health coaching, bariatric surgical interventions, and medications.
Paul Thompson
Industry Strategist, Payer
DXC Technology
|
|
| |
|
|
